KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $90.5 million.

  • Halozyme Therapeutics' Change in Receivables rose 29839.29% to $90.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $128.1 million, marking a year-over-year increase of 7248.7%. This contributed to the annual value of $128.1 million for FY2025, which is 7248.7% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Change in Receivables stood at $90.5 million for Q4 2025, which was up 29839.29% from $29.7 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Change in Receivables peaked at $90.5 million during Q4 2025, and registered a low of -$41.1 million during Q3 2021.
  • Over the past 5 years, Halozyme Therapeutics' median Change in Receivables value was $14.3 million (recorded in 2023), while the average stood at $14.1 million.
  • Examining YoY changes over the last 5 years, Halozyme Therapeutics' Change in Receivables showed a top increase of 74690.28% in 2021 and a maximum decrease of 26340.76% in 2021.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Change in Receivables stood at -$21.1 million in 2021, then skyrocketed by 136.71% to $7.8 million in 2022, then skyrocketed by 117.73% to $16.9 million in 2023, then soared by 34.51% to $22.7 million in 2024, then soared by 298.39% to $90.5 million in 2025.
  • Its Change in Receivables was $90.5 million in Q4 2025, compared to $29.7 million in Q3 2025 and $11.7 million in Q2 2025.